Amalgamated Financial’s Amylyx Pharmaceuticals AMLX Stock Holding History

Amalgamated Financial’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$23K	Buy	+1,763	New	+$39.8K	﹤0.01%	2693

Other funds holding AMLX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Amalgamated Financial's AMLX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Amylyx Pharmaceuticals (AMLX) in Q1 2022: 1,763 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #2693 among its holdings.

72 funds tracked by Wall St. Rank hold AMLX as of Q1 2022.

Amalgamated Financial held 1,763 shares of Amylyx Pharmaceuticals worth $23K as of Q1 2022.
Amylyx Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Amylyx Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2693 holding.
72 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.